Af­ter lay­ing off a fourth of its staff, gene ther­a­py start­up Swan­Bio sees fresh fi­nanc­ing as it heads to­wards the clin­ic

Just a few short weeks af­ter Swan­Bio laid off a quar­ter of its 60-per­son work­force, it has re­turned with $56 mil­lion in new fi­nanc­ing.

The lay­offs en­sued as the gene ther­a­py biotech was un­able to get new fi­nanc­ing in the first quar­ter of the year when its in­vestors backed out, End­points News had learned, but it ap­pears not all the in­vestors walked out. No­tably, one of Swan­Bio’s re­turn­ing in­vestors, Syn­cona, al­so owns 75% of the com­pa­ny. Its oth­er lead in­vestor this round, Mass Gen­er­al Brigham Ven­tures, was al­so a found­ing in­vestor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER